Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | CCR3 | P51677 | 3/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | TARDBP | Q13148 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544986 | 0.91 | KMT2A (0.41) | KDM4ERAB9AKMT2AMEN1EPHX2 | |
| SCHEMBL399032 | 0.91 | KMT2A (0.41) | KDM4ERAB9AKMT2AMEN1EPHX2 | |
| SCHEMBL4012403 | 0.91 | KMT2A (0.41) | KDM4ERAB9AKMT2AMEN1EPHX2 | |
| SCHEMBL4011647 | 0.86 | CCR3 (0.40) | RAB9AKMT2AMEN1CCR3 | |
| SCHEMBL399042 | 0.86 | CCR3 (0.40) | RAB9AKMT2AMEN1CCR3 | |
| SCHEMBL398795 | 0.86 | CCR3 (0.40) | RAB9AKMT2AMEN1CCR3 | |
| SCHEMBL400551 | 0.82 | ADRB2 (0.41) | KDM4ERAB9AKMT2AMEN1EPHX2 | |
| SCHEMBL400753 | 0.82 | ADRB2 (0.41) | KDM4ERAB9AKMT2AMEN1EPHX2 | |
| SCHEMBL4003553 | 0.82 | ADRB2 (0.41) | KDM4ERAB9AKMT2AMEN1EPHX2 | |
| SCHEMBL545169 | 0.82 | ADRB2 (0.44) | KDM4ERAB9AKMT2AMEN1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101617-B2 | Disubstituted ureas and uses thereof in treating heart failure | AMGEN, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090099198-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099198-A1 | Compounds, Compositions and Methods | TNNI3, TNNC1, TNNT2 | KDM4E 2421/4885RAB9A 2773/4885KMT2A 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.